Tower Research Capital LLC TRC reduced its stake in shares of Altimmune, Inc. (NASDAQ:ALT – Free Report) by 31.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,093 shares of the company’s stock after selling 9,214 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Altimmune were worth $85,000 as of its most recent SEC filing.
Several other hedge funds have also recently bought and sold shares of ALT. Charles Schwab Investment Management Inc. increased its stake in shares of Altimmune by 3.4% in the first quarter. Charles Schwab Investment Management Inc. now owns 104,222 shares of the company’s stock valued at $635,000 after buying an additional 3,402 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Altimmune by 2.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 177,865 shares of the company’s stock valued at $2,925,000 after buying an additional 3,492 shares in the last quarter. Vahanian & Associates Financial Planning Inc. increased its stake in shares of Altimmune by 25.1% in the first quarter. Vahanian & Associates Financial Planning Inc. now owns 21,430 shares of the company’s stock valued at $90,000 after buying an additional 4,300 shares in the last quarter. XTX Topco Ltd increased its stake in shares of Altimmune by 33.2% in the first quarter. XTX Topco Ltd now owns 19,665 shares of the company’s stock valued at $120,000 after buying an additional 4,898 shares in the last quarter. Finally, Algert Global LLC increased its stake in shares of Altimmune by 39.8% in the fourth quarter. Algert Global LLC now owns 18,560 shares of the company’s stock valued at $305,000 after buying an additional 5,280 shares in the last quarter. 66.99% of the stock is currently owned by institutional investors and hedge funds.
Altimmune Trading Up 4.7 %
Shares of ALT opened at $2.65 on Tuesday. Altimmune, Inc. has a 1 year low of $2.34 and a 1 year high of $23.49. The stock has a market cap of $139.63 million, a P/E ratio of -1.63 and a beta of -0.03. The stock’s 50-day moving average price is $3.05 and its two-hundred day moving average price is $5.13.
Wall Street Analyst Weigh In
A number of analysts have recently weighed in on the company. HC Wainwright lowered their target price on Altimmune from $50.00 to $15.00 and set a “buy” rating for the company in a research note on Monday, August 14th. B. Riley decreased their price target on Altimmune from $20.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, August 11th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $17.00.
Check Out Our Latest Research Report on Altimmune
Altimmune Profile
Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis.
Featured Articles
- Five stocks we like better than Altimmune
- 3 Monster Growth Stocks to Buy Now
- MarketBeat Week in Review – 8/28 – 9/1
- Health Care Stocks Explained: Why You Might Want to Invest
- 2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
- What Are Growth Stocks and Investing in Them
- Toyota vs Tesla: The Tortoise And The Hare Race Has A New Meaning
Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.
